DDInter712 DDInter1376
Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Famotidine {u} (Compound) binds {v} (Gene) SLC47A1
Famotidine {u} (Compound) upregulates {v} (Gene) IFNAR1
Famotidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Famotidine {u} (Compound) downregulates {v} (Gene) PCNA
Famotidine {u} (Compound) causes {v} (Side Effect) Jaundice
Famotidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Famotidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ketorolac
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Famotidine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Famotidine (Compound) binds SLC47A1 (Gene)
Famotidine (Compound) upregulates IFNAR1 (Gene)
Famotidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Famotidine (Compound) downregulates PCNA (Gene)
Famotidine (Compound) causes Jaundice (Side Effect)
Famotidine may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Famotidine may cause a minor interaction that can limit clinical effects when taken with Ketorolac
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine
Famotidine may lead to a major life threatening interaction when taken with Dasatinib